Clinically Applicable Inhibitors Impacting Genome Stability

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Anu PrakashEmer Bourke

Abstract

Advances in technology have facilitated the molecular profiling (genomic and transcriptomic) of tumours, and has led to improved stratification of patients and the individualisation of treatment regimes. To fully realize the potential of truly personalised treatment options, we need targeted therapies that precisely disrupt the compensatory pathways identified by profiling which allow tumours to survive or gain resistance to treatments. Here, we discuss recent advances in novel therapies that impact the genome (chromosomes and chromatin), pathways targeted and the stage of the pathways targeted. The current state of research will be discussed, with a focus on compounds that have advanced into trials (clinical and pre-clinical). We will discuss inhibitors of specific DNA damage responses and other genome stability pathways, including those in development, which are likely to synergistically combine with current therapeutic options. Tumour profiling data, combined with the knowledge of new treatments that affect the regulation of essential tumour signalling pathways, is revealing fundamental insights into cancer progression and resistance mechanisms. This is the forefront of the next evolution of advanced oncology medicine that w...Continue Reading

References

Apr 12, 1996·Science·C E YuG D Schellenberg
Apr 1, 1996·Current Opinion in Genetics & Development·J E Brownell, C D Allis
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WebbM Meehan
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K R Hande
May 13, 1999·Nature Genetics·S KitaoY Furuichi
Jul 15, 2000·Journal of Computer-aided Molecular Design·P FuretP Imbach
Feb 24, 2001·Annals of the New York Academy of Sciences·L F LiuS P Sim
Feb 24, 2001·Annals of the New York Academy of Sciences·J H SchellensA H Schinkel
Feb 27, 2001·Mutation Research·A D Bolzán, M S Bianchi
Mar 21, 2001·Human Molecular Genetics·S B BaylinJ G Herman
May 30, 2001·Mutation Research·L H Thompson, D Schild
Aug 11, 2001·Science·T Jenuwein, C D Allis
Aug 22, 2002·Current Cancer Drug Targets·Ron H J MathijssenAlex Sparreboom
Sep 6, 2002·Oncogene·M Christine Hollander, Albert J Fornace
Sep 24, 2002·The Journal of Biological Chemistry·Baoguang ZhaoBin-Bing S Zhou
Sep 25, 2002·Bioorganic & Medicinal Chemistry Letters·Michael L CurtinSteven K Davidsen
Oct 4, 2002·Developmental Cell·Zhihong ChenBrian David Dynlacht
Nov 5, 2002·Nature Reviews. Cancer·Erich A Nigg
Nov 14, 2002·The Biochemical Journal·Annemieke J M de RuijterAndré B P van Kuilenburg
Nov 21, 2002·Nature·Luca PellegriniAshok R Venkitaraman
Mar 4, 2003·Nature Reviews. Cancer·Yosef Shiloh
Apr 5, 2003·Cancer Cell·Osamu Tetsu, Frank McCormick
Jun 13, 2003·Trends in Genetics : TIG·Michael J CarrozzaJacques Côté
Nov 14, 2003·Journal of Medicinal Chemistry·Thomas A MillerSandro Belvedere
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Aug 6, 2004·The Journal of Biological Chemistry·Brandon MetgeRon Balczon
Dec 14, 2004·Oncogene·Spencer J CollisAntony R Parker

❮ Previous
Next ❯

Citations

May 1, 2019·International Journal of Molecular Sciences·Amreena SuriSimone T Sredni
Nov 28, 2019·Journal of Hematology & Oncology·Andrea Ghelli Luserna di RoràGiorgia Simonetti
Feb 6, 2020·Pharmaceutical Patent Analyst·James Al Brown
Dec 3, 2020·Frontiers in Oncology·Donglu WuDa Liu
Apr 20, 2021·Apoptosis : an International Journal on Programmed Cell Death·Eloise DucreyPatrycja Nowak-Sliwinska

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
acetylation
xenografts
chemical modifications
histone acetylation

Clinical Trials Mentioned

NCT00104364
NCT01989325
NCT02092922
NCT02384083
NCT01954316
NCT03187288
NCT02588105
NCT02487095
NCT03188965
NCT01051635

Software Mentioned

MMEJ

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

© 2022 Meta ULC. All rights reserved